Amphotericin B induced abnormalities in human platelets

K B Pastakia, N E Brownson, D A Terle, B J Poindexter

Abstract

**Aims**—To investigate in vitro the effect of amphotericin B on platelets in order to understand poor platelet recovery in patients receiving platelet transfusions and amphotericin B simultaneously.

**Methods**—Washed platelets were isolated from platelet concentrates and exposed to amphotericin B (4 μg/ml) for one hour. Platelet function was assessed by aggregation response to thrombin (0-0.6 U/ml), serotonin release, response to hypotonic stress, and mean platelet volume. The expression of surface membrane glycoprotein (GP) Ib-IX complex, GPIIb-IIIa complex and CD62P (P-selectin) was examined by flow cytometry using fluorescence labelled monoclonal antibodies. Heterotypic cell adhesion was measured in amphotericin B treated platelets co-incubated with isolated, autologous polymorphonuclear leucocytes (PMN) by flow cytometric analysis.

**Results**—Amphotericin B induced platelet dysfunction. The rate of aggregation by thrombin, serotonin uptake and thrombin induced release of serotonin, and the response of platelets to hypotonic stress were inhibited. There was up to a two-fold increase in the mean platelet volume. The expression of platelet surface GPIb-IX and GPIIb-IIIa was not affected. P-selectin, normally expressed only on the surface of activated platelets, was also expressed on unactivated platelets. Amphotericin B increased platelet adherence to PMN and the number of platelets bound per PMN.

**Conclusions**—In vitro, amphotericin B induces P-selectin expression on the surface of unactivated platelets and increases platelet adhesion to PMN, which is exacerbated by storage. Platelet dysfunction resulting from exposure to amphotericin B may contribute to poor platelet recovery in vivo when amphotericin B is administered concomitantly with platelet transfusion.


Keywords: amphotericin B, platelets, surface membrane glycoprotein, flow cytometry.

Systemic administration of amphotericin B is a standard treatment for mycotic infections. Immunocompromised, critically ill, or patients with cancer often require the simultaneous administration of amphotericin B and blood components. Amphotericin B given concomitantly with platelet transfusion is associated with poor platelet recovery.1-4 The recovery of stored platelets 12–18 hours post-transfusion, relative to fresh platelets, decreased from 89% in clinically stable patients to 65% in patients receiving intravenous amphotericin B.5 In vivo, platelets play a central role in haemostasis by the processes of adhesion and aggregation. Interactions between platelets (haemostatic cells) and inflammatory cells such as polymorphonuclear leucocytes (PMN) are of importance for both haemostasis and inflammation.

Amphotericin B is a lipophilic antibiotic which binds to membrane sterols of mammalian cells, including those in the blood.6 7 This leads to destruction of membrane integrity, increased cell permeability, leakage of cellular contents, and subsequent cell lysis. In vitro, amphotericin B exacerbates a platelet surface membrane lesion, characterised as "pits",8 and decreases the expression of surface membrane glycoprotein (GP) Ib in stored platelets.9

In the present study we have characterised the in vitro effects of amphotericin B on platelets. Platelet function was assessed by thrombin induced aggregation, serotonin release, hypotonic stress response, and mean platelet volume. The platelet surface is the primary site of exposure to amphotericin B. We have examined the effect of the antibiotic on the surface expression of platelet membrane GPIb-IX complex, GPIIb-IIIa complex and P-selectin and on platelet-PMN adhesion using flow cytometry.

**Methods**

**PLATELET PREPARATION**

Platelets were obtained as platelet concentrates by automated platelepheresis or as platelet rich plasma, from normal human blood collected in 1/11 volume anticoagulant citrate dextrose solution (75 mM trisodium citrate, 38 mM citric acid, 124 mM dextrose) as described previously.10 11 Platelet concentrates were stored in polyolefin bags (Fenwal PL732; Baxter Healthcare Corp., Deerfield, Illinois, USA) on a rotator at room temperature (20-24°C). Incubations in the experiments were carried out at room temperature unless otherwise specified. Washed, unactivated platelets were isolated from platelet concentrates or from platelet rich plasma by centrifugation at 1000 × g for 10 minutes in the presence of 1 μM prostaglandin E1 (PGE1) and resuspen-
sion at a density of 5 × 10⁵/ml in Tyrode’s-
HEPES buffer (TH; 137 mM NaCl, 2.7 mM
KCl, 0.42 mM NaH₂PO₄, 12.5 mM
NaHCO₃, 2.0 mM MgCl₂, 5.5 mM
D-glucose, 5.0 mM HEPES, and 3.5 mg/ml
bovine serum albumin, pH 7.4).

AMPHOTERICIN B TREATMENT
Amphotericin B (Life Technologies, Gaithers-
burg, Maryland, USA), 250 µg/ml stock
solution in saline, was added at a final concentra-
tion of 4 µg/ml to the platelet suspension in
TH buffer. Platelets were incubated with the
antibiotic at 37 °C for one hour. An equal vol-
ume of saline was added to control samples. The
concentration of 4 µg/ml amphotericin B was
chosen for studies as representative of thera-
petic peak serum concentrations reported with
intravenous amphotericin B.1 In preliminary
experiments, thrombin induced platelet
aggregation was studied after treatment with 1, 2
and 4 µg/ml amphotericin B and the mean
platelet volume was determined after treat-
ment with 1–32 µg/ml amphotericin B.

PLATELET COUNTING AND SIZE ANALYSIS
Platelet counts and size analysis were per-
formed on a System 9000 Hematology Series
1

PLATELET AGGREGATION
Amphotericin B treated platelets and untreated
controls (150 µl) were incubated in a microtitre
plate with human α-thrombin (lot H2; FDA,
Bethesda, Maryland, USA) added at concen-
trations of 0.18–0.6 U/ml. Aggregation was
monitored as a change in the absorbance at
650 nm (A₅₅₀) using a Vmax Kinetic Micro-
plate Reader (Molecular Devices Corporation,
Menlo Park, California, USA).12

HYPORTONIC STRESS RESPONSE
Platelets (50 µl of 1 ×10¹²/ml) treated with 4
µg/ml amphotericin B or untreated, control
platelets were added to 100 µl TH (buffer con-
trols, −stress) or 100 µl distilled water
(+stress). Hypotonic stress response was mea-
sured as a change in A₅₅₀ with time using a
Vmax Kinetic Microplate Reader.

SEROTONIN UPTAKE AND RELEASE ASSAY
Serotonin release was assayed as described previ-
ously.13 Amphotericin B treated platelets and
controls (5 × 10⁹/ml) were incubated with
0.05 µCi/ml [¹⁴C]serotonin (New England
Nuclear, Boston, Massachusetts, USA) for 30
minutes at 37°C. Samples were washed once in
TH buffer with 1 µM PGE₁, and resuspended in
TH buffer at 5 × 10⁹/ml. An aliquot was used to
measure the extent of serotonin uptake by
scintillation counting. Imipramine (6.8 µM)
was added to the final platelet suspension to
prevent re-uptake of serotonin following
thrombin stimulation. Aliquots (1 ml) were
activated by 0.02–4.0 U/ml thrombin for two
minutes. Platelets were then fixed by adding

2.5 ml cold 1.5 M formaldehyde and incuba-
tion at 4 °C for 10 minutes. The platelet
suspension was centrifuged at 3200 × g and the
serotonin released from platelets was measured
in the supernatant. The serotonin release at
various thrombin concentrations was ex-
pressed as a percent of the total extent of sero-
tonin uptake in the platelets.

PMN ISOLATION
PMN were isolated from autologous human
blood as described previously.14 Briefly, PMN
were isolated by dextran sedimentation, den-
sity gradient centrifugation using Lymphocyte
Separation Medium (Organon Teknika, Dur-
ham, North Carolina, USA) and hypotonic
lysis of erythrocytes. PMN were washed three
times with and resuspended in calcium- and
magnesium-free Hank’s balanced salt solution
(HBSS; Life Technologies) to 10⁷/ml.

ANTIBODIES
The fluorescein isothiocyanate (FITC) conjug-
gated CD41 monoclonal antibody (clone P2; Immuno-
tech Inc., Westbrook, Maine, USA) recognises an epitope on GPIIb-IIIa complex.
The phycoerythrin (PE) conjugated CD62P
monoclonal antibody (clone AC1.2; Becton
Dickinson Immunocytometry Systems, San
Jose, California, USA) recognises the CD62P
(P-selectin) antigen, an α-granule membrane
protein that is externalised and expressed on
the plasma membrane of activated platelets. The
GPIb-IX monoclonal antibody (Immu-
notech Inc.) recognises an epitope only present
on the platelet membrane GPIb-IX complex.
This monoclonal antibody was labelled with
secondary goat anti-mouse IgG-FITC antise-
tiserum (Sigma, St Louis, Missouri, USA). All of
the monoclonal antibodies are of the IgG class.
The isotype control reagents conjugated to
either FITC or PE were purchased from
Becton Dickinson Immunocytometry Systems.

PREPARATION OF PLATELETS FOR FLOW
CYTOMETRY
Labelling of platelets with monoclonal anti-
body was carried out as described previ-
ously.13 Amphotericin B treated platelets were
diluted to 5 × 10⁹/ml in TH buffer containing either 5
mM EDTA for assessing monoclonal antibody
binding to GPIb-IX or 2 mM CaCl₂ (TH-Ca) for
binding to GPIIb-IIIa and P-selectin. Ali-
quots (100 µl) were incubated with saturating
concentrations of monoclonal antibody.
Thrombin (0.032–4.0 U/ml) was added and
samples were incubated for 30 minutes. After
15 minutes, a saturating concentration of goat
antimouse IgG-FITC secondary antibody was
added to samples in which unlabelled GPIb-IX
monoclonal antibody was used. The samples
were then fixed with an equal volume of 2%
formaldehyde in TH buffer for 30 minutes.
The samples were diluted to 0.5 ml in TH
buffer and analysed using flow cytometry.
Amphotericin B induced abnormalities in human platelets

Figure 1  Thrombin induced platelet aggregation after exposure for one hour to amphotericin B. Platelets (5 × 10⁵/ml) in TH were incubated with 0, 1, 2, or 4 μg/ml amphotericin B at 37°C and stimulated with thrombin (0.18 U/ml). Aggregation was measured as changes in light absorption (A₅₃₀) following addition of thrombin at time 0 minutes.

Figure 2  Effect of amphotericin B on mean platelet volume. Platelets (5 × 10⁵/ml) in TH were incubated with 0, 1, 2, 4, 8, 16, and 32 μg/ml amphotericin B for one hour at 37°C and the mean platelet volume was measured in a cell counter.

Results

PLATELET AGGREGATION
Exposure of platelets in TH buffer to increasing amphotericin B concentrations from 1 to 4 μg/ml for one hour at 37°C resulted in a decrease in their A₅₃₀ (fig 1). Increasing amphotericin B concentrations inhibited the thrombin induced rate of aggregation by 20–70%. The inhibitory effect of amphotericin B was observed at 0.18 U/ml thrombin (fig 1) and similarly at higher thrombin concentrations up to 0.6 U/ml (data not shown). The extent of aggregation was not affected. Examination by light microscopy of untreated platelets and platelets treated with 1–4 μg/ml amphotericin B did not reveal any notable difference in morphology.

MEAN PLATELET VOLUME
The effect on mean platelet volume of exposing platelets in TH buffer to varying concentrations of amphotericin B is shown in fig 2. In the presence of 4–32 μg/ml amphotericin B the mean platelet volume increased 1.4–2.6 fold. Platelet count was not affected. Platelets, after five days of storage, showed similar increases in the mean platelet volume on treatment with amphotericin B under the same conditions (data not shown).

HYPOTONIC STRESS RESPONSE
Hypotonic stress response was inhibited in platelets exposed to 4 μg/ml amphotericin B, as shown in fig 3. The A₅₃₀ of amphotericin B treated platelets was lower than the untreated platelets. Under hypotonic stress, the A₅₃₀ of the untreated platelets decreased initially and then increased, indicating partial recovery. The platelets exposed to antibiotic and subjected to hypotonic stress showed a decrease in A₅₃₀ which remained unchanged with time.

FLOW CYTOMETRY
A FACScan flow cytometer (Becton Dickinson Immunocytometry Systems) was used to acquire logarithmically amplified light scatter and fluorescence signals from 10 000 platelets in each sample. Platelets and PMN were identified by their characteristic forward and orthogonal light scatter and by CD41-FITC fluorescence as a platelet specific marker. Results are expressed as histograms of cell count versus log fluorescence intensity (FL1 or FL2) or bar graphs. Background binding, obtained from parallel assays with FITC or PE labelled isotype control monoclonal antibodies, was used to set a threshold (99% of control events below the threshold) for positive platelet fluorescence. The platelet fluorescence ratio, an estimate of the number of platelets bound to each neutrophil, was determined as described by Rinder et al.¹ The experiments were performed at least three times with single representative experiments shown in figs 5, 6 and 7.

STATISTICAL ANALYSIS
The data were analysed using a paired t test. Values are expressed as mean (SD). Differences were considered significant if p < 0.05.

PLATELET–PMN CO-INOCULATION ASSAY
Fixed, CD41-FITC labelled platelets (150 μl, 3 × 10⁵/ml) in TH-Ca buffer were added to viable PMN (150 μl, 3 × 10⁵/ml) to approximate the relative densities in normal blood, mixed by gentle inversion, incubated for 30 minutes, and analysed using flow cytometry.

SEROTONIN UPTAKE AND RELEASE
Amphotericin B strongly inhibited (85 (5)% total [³⁵S]serotonin uptake, as determined by scintillation counting. Serotonin release in amphotericin B treated platelets is also inhibited upon activation by thrombin (fig 4). The maximum serotonin released, at the highest thrombin concentration (4.0 U/ml), indicated that in control platelets 79 (3)% of total serotonin uptake was releasable, whereas in amphotericin B treated platelets 55 (9)% of total uptake was releasable.
**SURFACE EXPRESSION OF MEMBRANE GLYCOPROTEINS**

Thrombin induced a decrease in surface GPIIb-IX expression and an increase in GPIIb-IIIa expression in control and amphotericin B treated platelets (figs 5A and 5B). In fresh, unactivated platelets exposed to amphotericin B surface P-selectin was elevated compared with fresh, control platelets which do not express P-selectin (fig 5C). P-selectin expression was increased by thrombin concentrations of 0.16–4.0 U/ml in both control and amphotericin B treated platelets. Its expression was higher in treated platelets than in untreated ones at low thrombin (0.032 and 0.16 U/ml) concentrations.

The effect of amphotericin B on surface P-selectin expression in stored platelets is shown in fig 6. Surface P-selectin expression was undetectable in fresh platelets but increased with amphotericin B treatment (fig 6A). In five-day stored platelets, surface P-selectin expression was observed in untreated platelets and was significantly increased in amphotericin B treated platelets (fig 6B).

**ADHENSION OF PLATELETS TO PMN**

Isolated platelets and PMN were co-incubated as described. Figure 7 shows the histograms of a representative assay of the effect of amphotericin B on platelet adhesion to PMN. The platelets were labelled with anti-GPIIb-IIIaFITC monoclonal antibody. PMN events positive for the platelet marker fluorescence represent PMN with bound platelets. A threshold marker for platelet fluorescence was set using...
Amphotericin B induced abnormalities in human platelets

Amphotericin B induced platelet abnormalities in human platelets (fig 7A; bold line). Thrombin activated platelets, untreated or treated with amphotericin B, were bound by 98% and 80% of PMN, respectively (fig 7B; dashed and bold lines). Exposure of platelets to amphotericin B increased the number of unactivated platelets bound per PMN—that is, the mean platelet fluorescence ratio, from 2 to 9. The mean platelet fluorescence ratios of PMN binding activated platelets without and with amphotericin B were 10 and 9, respectively. The results of three experiments are summarised in table 1. The percentage of PMN binding unactivated platelets was significantly increased by treatment with amphotericin B (p < 0.003). Thrombin activation of untreated and treated platelets also increased the percentage of PMN binding platelets (p < 0.009). The platelet fluorescence ratio increased upon amphotericin B treatment of unactivated platelets (p < 0.004). Thrombin activation of untreated platelets increased the platelet fluorescence ratio (p < 0.02).

**Discussion**

Simultaneous administration of amphotericin B with transfusion of stored platelets induces an impressive decrease in in vivo platelet recovery and survival in myelosuppressed patients. In our in vitro studies we examined the effect of amphotericin B on platelet function and the expression of surface membrane glycoprotein in fresh and stored platelets. Exposure of washed platelets to therapeutic concentrations of amphotericin B (4 µg/ml) for one hour resulted in impaired function in both fresh and stored platelets. The rate of aggregation by thrombin, serotonin uptake and release, and response to hypotonic stress were inhibited, and the mean platelet volume was increased. Amphotericin B binds to sterols of mammalian cell membranes and functions as an ionophore, inducing extensive permeability to ions. Such an effect on the platelet membranes could result in the observed increase in the mean platelet volume on treatment with amphotericin B. The inhibition of serotonin uptake observed by us, could be the result of disruption of the transmembrane proton, Na⁺, and K⁺ gradients which are required for active transport of serotonin across the platelet plasma membrane. Inhibition of serotonin release may be because of its lower uptake on exposure to amphotericin B. Exposure of red blood cells to amphotericin B in vitro causes cell lysis subsequent to disruption of membrane permeability. However, in vivo increased cation pumping by healthy red cells compensates for the damage. Administration of amphotericin B with granulocyte transfusion has been reported to cause lethal pulmonary reactions, possibly from PMN lysis and release of proteases that damage the tissue. A more recent study, however, showed no detrimental interaction between granulocyte transfusion and amphotericin B. Studies of platelets using scanning electron microscopy show a significant increase in *"pit"* formation in stored platelets exposed to

---

**Table 1** Heterotypic adhesion of platelets to PMN. Results are expressed as mean (SD)

<table>
<thead>
<tr>
<th></th>
<th>PMN binding platelets (%)</th>
<th>Platelet fluorescence ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Unactivated</td>
<td>Activated</td>
</tr>
<tr>
<td>Control</td>
<td>52 (11)</td>
<td>99 (1)</td>
</tr>
<tr>
<td>Amphotericin B</td>
<td>83 (10)</td>
<td>89 (10)</td>
</tr>
</tbody>
</table>
amphotericin B. In platelet concentrates exposed to 4 µg/ml amphotericin B for six hours a partial loss of total GPIb in fresh and stored platelets and a decrease in the surface expression of GPIb in stored platelets were observed. Amphotericin B also inhibited ADP/epinephrine and ADP/collagen induced platelet aggregation in stored platelets.

We used flow cytometry in conjunction with glycoprotein specific monoclonal antibodies to define further the abnormality in platelet function. In concurrence with previous studies, we observed thrombin modulation of the platelet surface GPIb-IX and GPIb-IIIa. These changes were not affected by treatment with amphotericin B. However, P-selectin, which is externalised from the internal α-granules and expressed on activated platelets, was expressed on the surface of unactivated platelets exposed to amphotericin B. In five-day stored platelets surface P-selectin expression was increased not only upon amphotericin B treatment compared with amphotericin B treated fresh platelets. P-selectin expression on the platelet surface membrane is a marker of platelet activation and its expression on platelet surface membranes has been shown to correlate with storage and reduced recovery one hour post-transfusion. The reduced recovery and survival observed with simultaneous administration of stored platelets and amphotericin B in certain clinical conditions may result from increased P-selectin expression on the platelet surface that occurs during storage, being exacerbated by exposure to the antibiotic. Novel approaches have been developed recently to improve the delivery of amphotericin B. The administration of liposomal amphotericin B preparations has an improved toxicity profile compared with the standard preparation. Other antifungals increasingly used as alternatives to amphotericin B for treatment of systemic fungal infection include ketoconazole and fluconazole.

Adhesion of unactivated platelets to PMN was increased in amphotericin B treated platelets probably because of the surface expression of P-selectin which mediates platelet–PMN adhesion via the P-selectin glycoprotein ligand-1 receptor on the PMN surface. Surface expression of P-selectin is increased in stored platelets. Exacerbation of this platelet storage lesion by amphotericin B could lead to increased binding of platelets to leukocytes which may be a potent mechanism in vivo for the clearance of platelets transfused concomitantly with amphotericin B from the circulation.

Figure 7 Flow cytometric analysis of the effect of amphotericin B on platelet–PMN adhesion. Platelets in TH buffer were treated with amphotericin B, labelled with platelet specific, FITC conjugated CD41 (GPIb-IIIa) monoclonal antibody or an isotype control antibody (mouse IgG-FITC), activated with thrombin (0.2 U/ml) and fixed. Platelets and PMN were then co-incubated for 30 minutes. Events in the PMN gate which were platelet marker positive were analysed. In (A) and (B) the thin line histogram plots correspond to PMN events labelled with the isotype control (mouse IgG-FITC) used to set the threshold for positive platelet fluorescence. Histogram plots in (A) correspond to untreated (dashed line) and amphotericin B treated (bold line) unactivated platelets adhered to PMN. Histogram plots in (B) correspond to untreated (dashed line) and amphotericin B treated (bold line) activated platelets adhered to PMN. This experiment is representative of four separate experiments.

Amphotericin B induced abnormalities in human platelets